Work

VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.2533

Authors: David Michael Hyman, Jean-Yves Blay, Ian Chau, Noopur S. Raje, Maria Elena Elez Fernandez, Juergen Wolf, Florin Sirzen, Maria Luisa Veronese, Lada Mitchell, Igor Puzanov, Jose Baselga

Institutions: Memorial Sloan Kettering Cancer Center, Centre Léon Bérard, Royal Marsden NHS Foundation Trust, Massachusetts General Hospital, Vall d'Hebron Hospital Universitari, University Hospital Cologne, F. Hoffmann-La Roche AG, Vanderbilt University Medical Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W257954806

Cites:

Cited by: 21

Related to: 10